imiquimod has been researched along with anthralin in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Khan, W; Kommineni, N; Raza, K; Saka, R; Sathe, P | 1 |
Arnold-Schild, D; Bartneck, J; Grabbe, S; Hartmann, AK; Klein, M; Langguth, P; Meiser, SL; Muth, S; Pielenhofer, J; Probst, HC; Radsak, MP; Schild, H; Stassen, M | 1 |
3 other study(ies) available for imiquimod and anthralin
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model.
Topics: Administration, Cutaneous; Animals; Anthralin; Dermatologic Agents; Disease Models, Animal; Drug Carriers; Drug Liberation; Gels; Humans; Imiquimod; Lipids; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Ointments; Particle Size; Psoriasis; Severity of Illness Index; Skin; Treatment Outcome | 2019 |
Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection.
Topics: Adjuvants, Immunologic; Animals; Anthralin; CD8-Positive T-Lymphocytes; Dermatitis; Humans; Imiquimod; Immunization; Mice; Mice, Inbred C57BL; Neoplasms; Vaccination | 2023 |